Holen Sie sich die Stockscreener-App
45.84
0.95%
0.43
Handel nachbörslich:
46.55
0.71
+1.55%
Schlusskurs vom Vortag:
$45.41
Offen:
$45.41
24-Stunden-Volumen:
3.90M
Relative Volume:
1.04
Marktkapitalisierung:
$19.64B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$1.30B
KGV:
26.21
EPS:
1.7487
Netto-Cashflow:
$1.05B
1W Leistung:
-3.43%
1M Leistung:
+4.06%
6M Leistung:
+25.59%
1J Leistung:
+38.87%
1-Tages-Spanne:
$45.27
$45.94
1-Wochen-Bereich:
$44.94
$47.86
52-Wochen-Spanne:
$29.66
$47.86
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
45.84 | 19.45B | 2.35B | 1.30B | 1.05B | 1.7487 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.87 | 116.01B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.60 | 80.33B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
740.40 | 44.42B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.59 | 42.53B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
302.29 | 33.32B | 5.36B | 287.73M | 924.18M | 2.5229 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | UBS | Neutral → Buy |
| 2025-09-30 | Eingeleitet | Goldman | Buy |
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Royalty Pharma PLC $RPRX is Regal Partners Ltd's 10th Largest Position - MarketBeat
Royalty Pharma PLC $RPRX Stock Position Decreased by Rhenman & Partners Asset Management AB - MarketBeat
Neo Ivy Capital Management Buys New Position in Royalty Pharma PLC $RPRX - MarketBeat
Goodman Advisory Group LLC Purchases New Stake in Royalty Pharma PLC $RPRX - MarketBeat
CM Management LLC Takes $1.76 Million Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Plc Hits New 52-Week High of USD 47.86 - Markets Mojo
Vera Therapeutics Appoints Christopher Hite to Board of Directors - GlobeNewswire Inc.
Royalty Pharma (NASDAQ:RPRX) Reaches New 12-Month HighStill a Buy? - MarketBeat
Royalty Pharma Plc Hits New 52-Week High of USD 47.66 - Markets Mojo
Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 34,791 Shares - MarketBeat
Insider sales of common stock — Repare Therapeutics (NASDAQ: RPRX) - Stock Titan
RPRX SEC FilingsRoyalty Pharma Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Victory Capital Management Inc. Purchases 165,727 Shares of Royalty Pharma PLC $RPRX - MarketBeat
RPRX Earnings History & Surprises | EPS & Revenue Results | ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) - ChartMill
A Look At Royalty Pharma (RPRX) Valuation After Robust 2025 Results And Expansion Plans In Asia - Sahm
Royalty Pharma at TD Cowen Conference: Strategic Growth Insights - Investing.com Nigeria
Royalty Pharma plc (RPRX) Earns $51 Target as 2026 Growth Outlook Exceeds Expectations - Yahoo Finance
RPRX Technical Analysis & ETF Price Forecast - Intellectia AI
Royalty Pharma (RPRX) Passes Through 2% Yield Mark - Nasdaq
Royalty Pharma Plc Hits New 52-Week High of USD 46.37 - Markets Mojo
TD Asset Management Inc Acquires 91,136 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Quantbot Technologies LP Makes New $2.82 Million Investment in Royalty Pharma PLC $RPRX - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Buys 44,289 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) Achieves Record Growth and Hits Investment Targets Ahead of Schedule - Finviz
Zymeworks secures $250M royalty financing from Royalty Pharma - Investing.com South Africa
Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform - Utusan Malaysia
Royalty Pharma Appoints Kenneth Sun as Senior VP and Head of Asia - National Today
Affiliated holders sell large RPRX stakes (RPRX) in Feb 2026 trades - Stock Titan
Royalty Pharma Plc (RPRX): Investor Outlook With 11.57% Upside Potential - DirectorsTalk Interviews
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing - citybiz
Zymeworks Q4 Earnings Call Highlights - Yahoo Finance
Royalty Pharma PLC (NASDAQ:RPRX) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Royalty Pharma appoints Kenneth Sun to lead Asia expansion - Investing.com
Royalty Pharma appoints Kenneth Sun to lead Asia expansion By Investing.com - Investing.com Canada
Royalty Pharma Appoints Kenneth Sun as Senior Vice President - citybiz
Royalty Pharma plc Appoints Kenneth Sun as Senior Vice President and Head of Asia, Effective May 2026 - marketscreener.com
Zymeworks Secures $250 Mln Royalty Funding Deal With Royalty Pharma - Nasdaq
$250M cancer drug royalty deal extends Zymeworks’ cash runway - Stock Titan
Citigroup Inc. Trims Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Plc Hits New 52-Week High at $47.50 - Markets Mojo
RPRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TD Cowen Lifts PT on Royalty Pharma Plc (RPRX) to $50 from $45, Here's Why - Finviz
TD Cowen Lifts PT on Royalty Pharma Plc (RPRX) to $50 from $45, Here’s Why - Insider Monkey
12 Cheap Biotech Stocks to Buy Now - Insider Monkey
Royalty Pharma stock hits 52-week high at 46.14 USD By Investing.com - Investing.com Australia
Cowen Maintains Buy on Royalty Pharma plc (RPRX) Feb 27, 2026 - Meyka
TD Cowen raises Royalty Pharma stock price target to $50 on growth - Investing.com UK
Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week HighWhat's Next? - MarketBeat
Royalty Pharma (RPRX) PT Raised to $50 at TD Cowen - StreetInsider
Royalty Pharma stock hits 52-week high at 46.14 USD - Investing.com South Africa
Royalty Pharma PLC $RPRX Shares Sold by Vanguard Group Inc. - MarketBeat
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):